NO20071005L - Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer - Google Patents

Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer

Info

Publication number
NO20071005L
NO20071005L NO20071005A NO20071005A NO20071005L NO 20071005 L NO20071005 L NO 20071005L NO 20071005 A NO20071005 A NO 20071005A NO 20071005 A NO20071005 A NO 20071005A NO 20071005 L NO20071005 L NO 20071005L
Authority
NO
Norway
Prior art keywords
cancer
pyrimidones
enantiomers
prevention
applications
Prior art date
Application number
NO20071005A
Other languages
English (en)
Inventor
Michael Howard Block
Jayachandran Ezhuthachan
Brian Aquila
Audrey Davies
Timothy Pontz
Maria-Elena Theoclitou
Xiaolan Zheng
Daniel John Russell
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37904998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071005(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/GB2005/003207 external-priority patent/WO2006018628A1/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20071005L publication Critical patent/NO20071005L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Foreliggende oppfinnelse angår nye forbindelser som har strukturell formel (I) og deres farmasøytiske preparater og fremgangsmåter for anvendelse derav. Disse nye forbindelsene kan anvendes for behandling eller forebygging av kreft.
NO20071005A 2004-08-18 2007-02-21 Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer NO20071005L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60236604P 2004-08-18 2004-08-18
PCT/GB2005/003207 WO2006018628A1 (en) 2003-03-07 2005-08-16 Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer

Publications (1)

Publication Number Publication Date
NO20071005L true NO20071005L (no) 2007-05-16

Family

ID=37904998

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071005A NO20071005L (no) 2004-08-18 2007-02-21 Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer

Country Status (18)

Country Link
US (3) US20080293744A1 (no)
EP (1) EP1781674A1 (no)
JP (1) JP2008509977A (no)
KR (1) KR20070046176A (no)
CN (1) CN101027309B (no)
AU (1) AU2005273705B8 (no)
BR (1) BRPI0514390A (no)
CA (1) CA2575188A1 (no)
IL (1) IL180810A0 (no)
MX (1) MX2007001953A (no)
MY (1) MY141233A (no)
NO (1) NO20071005L (no)
RU (1) RU2447077C2 (no)
SA (1) SA05260258B1 (no)
TW (1) TW200616977A (no)
UA (1) UA89201C2 (no)
UY (1) UY29070A1 (no)
ZA (1) ZA200701082B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20125635B (en) * 2007-11-13 2012-09-10 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
EP2845856A1 (en) * 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
UA121539C2 (uk) 2011-09-02 2020-06-25 Інсайт Холдинґс Корпорейшн Гетероцикліламіни як інгібітори рі3к
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
UA122332C2 (uk) 2015-02-27 2020-10-26 Інсайт Корпорейшн Солі інгібітора pi3k і способи їх отримання
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2025539264A (ja) * 2022-11-10 2025-12-04 リボメトリックス，インコーポレイティド ｅＩＦ４Ｅ阻害剤としての化合物及び組成物、ならびにそれらの使用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792767A (en) 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
US6262058B1 (en) 1996-03-11 2001-07-17 Syngenta Crop Protection, Inc. Pyrimidin-4-one derivatives as pesticide
CN100340559C (zh) 1998-12-23 2007-10-03 布里斯托尔-迈尔斯斯奎布药品公司 作为凝血因子xa抑制剂的含氮杂双环
ATE286033T1 (de) 1999-09-16 2005-01-15 Curis Inc Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
ES2263501T3 (es) 1999-10-27 2006-12-16 Cytokinetics, Inc. Procedimiento y composiciones que utilizan quinazolinonas.
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
US20020165240A1 (en) 2001-03-29 2002-11-07 Kimball Spencer David Method of treating proliferative diseases using Eg5 inhibitors
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US20030096813A1 (en) 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
AU2002363429B2 (en) * 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003043995A1 (en) * 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
AU2002363960B2 (en) * 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2003049679A2 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
ATE424388T1 (de) * 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
CA2467726A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
US7378411B2 (en) 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
AU2003213092A1 (en) 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
DE60333094D1 (de) * 2002-04-17 2010-08-05 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
EP1503993A4 (en) 2002-05-09 2006-05-03 Cytokinetics Inc COMPOUNDS, METHODS AND COMPOSITIONS
JP2005530785A (ja) * 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
AU2003231799A1 (en) 2002-05-23 2003-12-12 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2485343A1 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1513820A4 (en) * 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1556357A4 (en) 2002-06-14 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1539727B1 (en) 2002-07-17 2009-02-18 Cytokinetics, Inc. Compounds, compositions, and methods for treating cellular proliferative diseases
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
AU2003262747A1 (en) 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
JP2006501306A (ja) 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
EP1558589A4 (en) 2002-10-11 2008-01-09 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
PL375889A1 (en) 2002-10-11 2005-12-12 Cytokinetics, Inc. Compounds for treating cellular proliferative diseases, compositions containing them and their application
JP2006515886A (ja) 2003-01-17 2006-06-08 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
AR050920A1 (es) 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
JP3947758B2 (ja) 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
JP2006523232A (ja) 2003-04-10 2006-10-12 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
EP1620092A4 (en) 2003-05-07 2008-04-16 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
WO2005013888A2 (en) 2003-05-14 2005-02-17 Cytokinetics, Inc. Compounds, compositions and methods
EP1622878A4 (en) 2003-05-15 2008-04-09 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
EP1636225B1 (en) * 2003-06-20 2010-02-24 Novartis Vaccines and Diagnostics, Inc. Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents
EP1670456A2 (en) * 2003-10-06 2006-06-21 Cytokinetics, Inc. Compounds, compositions and methods
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
WO2005051922A1 (en) 2003-11-25 2005-06-09 Chiron Corporation Quinazolinone compounds as anticancer agents
JP2007513154A (ja) 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
PT1732926E (pt) * 2004-04-06 2009-04-03 Novartis Vaccines & Diagnostic Inibidores de cinesinas mitóticas
JP2008502721A (ja) 2004-05-21 2008-01-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 分裂キネシンインヒビターとしての置換キノリン誘導体
JP4836280B2 (ja) 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物
RU2007109867A (ru) 2004-08-18 2008-09-27 Астразенека Аб (Se) Выбранные конденсированные гетероциклы и их применение
US20060041128A1 (en) 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
EP1807399A2 (en) * 2004-10-19 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Indole and benzimidazole derivatives

Also Published As

Publication number Publication date
TW200616977A (en) 2006-06-01
AU2005273705B2 (en) 2009-12-10
US20080293744A1 (en) 2008-11-27
UY29070A1 (es) 2006-03-31
US20060041129A1 (en) 2006-02-23
US7498333B2 (en) 2009-03-03
CN101027309A (zh) 2007-08-29
UA89201C2 (ru) 2010-01-11
SA05260258B1 (ar) 2009-12-22
RU2447077C2 (ru) 2012-04-10
EP1781674A1 (en) 2007-05-09
AU2005273705B8 (en) 2010-01-28
MX2007001953A (es) 2007-05-09
IL180810A0 (en) 2007-06-03
AU2005273705A1 (en) 2006-02-23
RU2007109866A (ru) 2008-09-27
JP2008509977A (ja) 2008-04-03
ZA200701082B (en) 2008-07-30
KR20070046176A (ko) 2007-05-02
BRPI0514390A (pt) 2008-06-10
CA2575188A1 (en) 2006-02-23
US20090099210A1 (en) 2009-04-16
MY141233A (en) 2010-03-31
CN101027309B (zh) 2010-10-27

Similar Documents

Publication Publication Date Title
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
SA521422270B1 (ar) Apol1 مثبطات لـ وطرق لاستخدامها
EA202092003A1 (ru) Соединения для лечения болезни гентингтона
WO2018134685A3 (en) Compounds
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
NO20081454L (no) Met-kinaseinhibitorer
EA201370122A1 (ru) Фармацевтические составы, содержащие ингибиторы деацетилазы гистонов
DK2358717T3 (da) Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
NO20081636L (no) FAP - inhibitorer
NO20061197L (no) Proteasominhibitorer og fremgangsmater for anvendelse av samme
NO20071521L (no) Nye fenylaminopyrimidin derivater som hemmere av BCR-ABL kinase
DE60331219D1 (de) Azaindole als hemmstoffe von c-jun n-terminalen kinasen
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
NO20083568L (no) Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser
EA200870391A1 (ru) Тетрагидропирролопиримидиндионы и их применение в качестве ингибиторов эластазы нейтрофилов человека
NO20080150L (no) Inhibitorer av AKT-aktivitet
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20060230L (no) Nye aminobenzofenonforbindelser
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application